- Home
- ARTL vs INM Comparison
ARTL vs INM Comparison
Compare ARTL & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARTL
- INM
- Stock Information
- Founded
- ARTL 2011
- INM 1981
- Country
- ARTL United States
- INM Canada
- Employees
- ARTL N/A
- INM N/A
- Industry
- ARTL Biotechnology: Pharmaceutical Preparations
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- ARTL Health Care
- INM Health Care
- Exchange
- ARTL Nasdaq
- INM Nasdaq
- Market Cap
- ARTL 3.7M
- INM 3.4M
- IPO Year
- ARTL N/A
- INM N/A
- Fundamental
- Price
- ARTL $1.21
- INM $4.95
- Analyst Decision
- ARTL Strong Buy
- INM
- Analyst Count
- ARTL 2
- INM 0
- Target Price
- ARTL $5.50
- INM N/A
- AVG Volume (30 Days)
- ARTL 28.9K
- INM 26.6K
- Earning Date
- ARTL 11-12-2024
- INM 02-11-2025
- Dividend Yield
- ARTL N/A
- INM N/A
- EPS Growth
- ARTL N/A
- INM N/A
- EPS
- ARTL N/A
- INM N/A
- Revenue
- ARTL N/A
- INM $4,960,506.00
- Revenue This Year
- ARTL N/A
- INM N/A
- Revenue Next Year
- ARTL N/A
- INM N/A
- P/E Ratio
- ARTL N/A
- INM N/A
- Revenue Growth
- ARTL N/A
- INM 5.17
- 52 Week Low
- ARTL $0.91
- INM $2.42
- 52 Week High
- ARTL $1.75
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- ARTL 64.07
- INM 55.90
- Support Level
- ARTL $1.09
- INM $4.07
- Resistance Level
- ARTL $1.19
- INM $5.41
- Average True Range (ATR)
- ARTL 0.06
- INM 0.39
- MACD
- ARTL 0.01
- INM 0.01
- Stochastic Oscillator
- ARTL 100.00
- INM 67.83
About ARTL Artelo Biosciences Inc.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.